Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies.

Uusi-Kerttula H, Davies JA, Thompson JM, Wongthida P, Evgin L, Shim KG, Bradshaw A, Baker AT, Rizkallah PJ, Jones R, Hanna L, Hudson E, Vile RG, Chester JD, Parker AL.

Clin Cancer Res. 2018 Sep 1;24(17):4215-4224. doi: 10.1158/1078-0432.CCR-18-1089. Epub 2018 May 24.

PMID:
29798908
2.

The role of ORF3 accessory protein in replication of cell-adapted porcine epidemic diarrhea virus (PEDV).

Wongthida P, Liwnaree B, Wanasen N, Narkpuk J, Jongkaewwattana A.

Arch Virol. 2017 Sep;162(9):2553-2563. doi: 10.1007/s00705-017-3390-5. Epub 2017 May 4.

PMID:
28474223
3.

Influenza B virus M2 protein can functionally replace its influenza A virus counterpart in promoting virus replication.

Wanitchang A, Wongthida P, Jongkaewwattana A.

Virology. 2016 Nov;498:99-108. doi: 10.1016/j.virol.2016.08.016. Epub 2016 Aug 25.

4.

In Vitro and In Vivo Attenuation of Vesicular Stomatitis Virus (VSV) by Phosphoprotein Deletion.

Wongthida P, Jengarn J, Narkpuk J, Koonyosying P, Srisutthisamphan K, Wanitchang A, Leaungwutiwong P, Teeravechyan S, Jongkaewwattana A.

PLoS One. 2016 Jun 17;11(6):e0157287. doi: 10.1371/journal.pone.0157287. eCollection 2016.

5.

Deciphering the biology of porcine epidemic diarrhea virus in the era of reverse genetics.

Teeravechyan S, Frantz PN, Wongthida P, Chailangkarn T, Jaru-Ampornpan P, Koonpaew S, Jongkaewwattana A.

Virus Res. 2016 Dec 2;226:152-171. doi: 10.1016/j.virusres.2016.05.003. Epub 2016 May 20. Review.

PMID:
27212685
6.

Mechanistic study of intertypic nucleoprotein complex formation and its inhibitory effect toward influenza A virus.

Narkpuk J, Jaru-Ampornpan P, Subali T, Bertulfo FC, Wongthida P, Jongkaewwattana A.

Virology. 2015 Nov;485:104-15. doi: 10.1016/j.virol.2015.06.032. Epub 2015 Jul 25.

7.

Genetic manipulation of porcine epidemic diarrhoea virus recovered from a full-length infectious cDNA clone.

Jengarn J, Wongthida P, Wanasen N, Frantz PN, Wanitchang A, Jongkaewwattana A.

J Gen Virol. 2015 Aug;96(8):2206-18. doi: 10.1099/vir.0.000184. Epub 2015 May 15.

PMID:
25979733
8.

Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer.

Rommelfanger DM, Wongthida P, Diaz RM, Kaluza KM, Thompson JM, Kottke TJ, Vile RG.

Cancer Res. 2012 Sep 15;72(18):4753-64. doi: 10.1158/0008-5472.CAN-12-0600. Epub 2012 Jul 26.

9.

Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.

Pulido J, Kottke T, Thompson J, Galivo F, Wongthida P, Diaz RM, Rommelfanger D, Ilett E, Pease L, Pandha H, Harrington K, Selby P, Melcher A, Vile R.

Nat Biotechnol. 2012 Mar 18;30(4):337-43. doi: 10.1038/nbt.2157.

10.

Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors.

Kottke T, Errington F, Pulido J, Galivo F, Thompson J, Wongthida P, Diaz RM, Chong H, Ilett E, Chester J, Pandha H, Harrington K, Selby P, Melcher A, Vile R.

Nat Med. 2011 Jun 19;17(7):854-9. doi: 10.1038/nm.2390. Erratum in: Nat Med. 2012 Sep;18(9):1445.

11.

Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.

Wongthida P, Diaz RM, Pulido C, Rommelfanger D, Galivo F, Kaluza K, Kottke T, Thompson J, Melcher A, Vile R.

Hum Gene Ther. 2011 Nov;22(11):1343-53. doi: 10.1089/hum.2010.216. Epub 2011 Apr 11.

12.

Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.

Willmon C, Diaz RM, Wongthida P, Galivo F, Kottke T, Thompson J, Albelda S, Harrington K, Melcher A, Vile R.

Mol Ther. 2011 Jan;19(1):140-9. doi: 10.1038/mt.2010.224. Epub 2010 Oct 26.

13.

VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.

Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Melcher A, Vile R.

Mol Ther. 2011 Jan;19(1):150-8. doi: 10.1038/mt.2010.225. Epub 2010 Oct 19.

14.

Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer.

Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Pulido J, Pavelko K, Pease L, Melcher A, Vile R.

Cancer Res. 2010 Jun 1;70(11):4539-49. doi: 10.1158/0008-5472.CAN-09-4658. Epub 2010 May 18.

15.

Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.

Galivo F, Diaz RM, Wongthida P, Thompson J, Kottke T, Barber G, Melcher A, Vile R.

Gene Ther. 2010 Feb;17(2):158-70. doi: 10.1038/gt.2009.161. Epub 2009 Dec 17.

16.

Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.

Galivo F, Diaz RM, Thanarajasingam U, Jevremovic D, Wongthida P, Thompson J, Kottke T, Barber GN, Melcher A, Vile RG.

Hum Gene Ther. 2010 Apr;21(4):439-50. doi: 10.1089/hum.2009.143.

17.

Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.

Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J, Kottke T, Federspiel M, Barber G, Albelda SM, Vile RG.

Cancer Res. 2009 Oct 1;69(19):7713-20. doi: 10.1158/0008-5472.CAN-09-1013. Epub 2009 Sep 22.

18.

Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.

Kottke T, Diaz RM, Kaluza K, Pulido J, Galivo F, Wongthida P, Thompson J, Willmon C, Barber GN, Chester J, Selby P, Strome S, Harrington K, Melcher A, Vile RG.

Mol Ther. 2008 Dec;16(12):1910-8. doi: 10.1038/mt.2008.212. Epub 2008 Sep 30.

19.

Treg Depletion-enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic Virus.

Kottke T, Galivo F, Wongthida P, Maria Diaz R, Thompson J, Jevremovic D, Barber GN, Hall G, Chester J, Selby P, Harrington K, Melcher A, Vile RG.

Mol Ther. 2008 Jul;16(7):1217-1226. doi: 10.1038/mt.2008.83. Epub 2016 Dec 8.

PMID:
28178481
20.

Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus.

Kottke T, Galivo F, Wongthida P, Diaz RM, Thompson J, Jevremovic D, Barber GN, Hall G, Chester J, Selby P, Harrington K, Melcher A, Vile RG.

Mol Ther. 2008 Jul;16(7):1217-26. doi: 10.1038/mt.2008.83. Epub 2008 Apr 22.

21.

Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy.

Qiao J, Kottke T, Willmon C, Galivo F, Wongthida P, Diaz RM, Thompson J, Ryno P, Barber GN, Chester J, Selby P, Harrington K, Melcher A, Vile RG.

Nat Med. 2008 Jan;14(1):37-44. Epub 2007 Dec 9.

PMID:
18066076
22.

Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.

Diaz RM, Galivo F, Kottke T, Wongthida P, Qiao J, Thompson J, Valdes M, Barber G, Vile RG.

Cancer Res. 2007 Mar 15;67(6):2840-8.

23.

An essential role for LEDGF/p75 in HIV integration.

Llano M, Saenz DT, Meehan A, Wongthida P, Peretz M, Walker WH, Teo W, Poeschla EM.

Science. 2006 Oct 20;314(5798):461-4. Epub 2006 Sep 7.

Supplemental Content

Loading ...
Support Center